Protocolnummer: NL 47475.000.14


Randomized Phase lll Study Comparing a Non-myeloblative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of Tumor Infiltrating Lymphocytes and Interleukin-2 to Standard Ipilimumab treatment in Metastatic Melanoma.


  • Antoni van Leeuwenhoek (NKI) ziekenhuis Amsterdam


Arm A- ipilimumab 3mg/kg 4 times or Arm B - Tumor Infiltrating lymphocytes ( 1:1 randomized)

Belangrijkste in/exclusiecriteria

In: a resectable metastatic lesion (= or > 3 cm) and willing to undergo a resection for experimental purposes, absolute neutrophil count greater than 1.5 x 109/L without support of filgrastim, platelet count greater than 100x 109/L , seronegative for HIV antibody and lues. Ex: metastatic ocular or mucosal melanoma, history of more than two CNS metastases, respiratory distress, coronary revascularization.


Prof. J. Haanen